Do you want to read an article? Please log in or register.
Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors
Lung Cancer
Related content
Lung Cancer
Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis
J Clin Med
Çelik S, Kavak EE, Zeynelgil E, İmamoğlu Gİ, Dilli İ, Karatlı S, Atak M, Altınbaş M, Eren T
doi: 10.3390/jcm15072475
Interstitial Lung DiseaseLung Cancer
Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study
Thorax
Karayama M, Miyashita K, Inoue Y, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Inui N, Suda T
doi: 10.1136/thorax-2025-223430
Lung Cancer
Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco
Clin Cancer Res
Gariazzo E, Elkrief A, Concannon K, Ognissanti D, Dodi A, Favorito V, Di Federico A, De Giglio A, Brunetti L, Santo V, Pecci F, Aldea M, Garbo E, Alessi JV, LoPiccolo J, Paoloni F, Nishino M, Sholl LM, Florez N, Rotow J, Frumm SM, Hong L, Zhang J, Gibbons D, Wang X, Landi L, Cipriani L, Rakaee M, Cortellini A, Tiseo M, Cappuzzo F, Ardizzoni A, Awad MM, Heymach JV, Scalera S, Maugeri-Saccà M, Metro G, Vokes N, Schoenfeld A, Ricciuti B
doi: 10.1158/1078-0432.CCR-25-4793
RECOMMENDED
Lung Cancer
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lee J, Kim M, Han HJ, Kim S, Suh HS
doi: 10.1016/j.lungcan.2025.108682
Lung Cancer
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis
Semin Oncol
Ganatra N, Thompson J, Desai R, Doshi J, Jain P, Pasnoor DS, Jain A
doi: 10.1016/j.seminoncol.2025.152431
Lung Cancer
CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46)
Lung Cancer
Martin LW, Wang X, Kozono D, Urbanic J, Graziano S, Osarogiagbon R, Mehran R, Wain J, Bestvina C, Wolf S, Patel JD, Stinchcombe T
doi: 10.1016/j.lungcan.2026.109374
Lung Cancer
Retifanlimab versus placebo in combination with platinum-based chemotherapy in patients with first-line non-squamous or squamous metastatic non-small-cell lung cancer (POD1UM-304): a phase 3, multiregional, placebo-controlled, double-blind, randomised study
Lancet Respir Med
Lu S, Vynnychenko O, Kulyaba Y, Kuchava V, Ibrahim A, Moiseenko F, Arslan C, Nguyen DT, Petrovic M, Cicin I, Bibichadze K, Cil T, Shi J, Olmez OF, Gogishvili M, Artac M, Nguyen HG, Cornfeld M, Tian C, Munteanu MC, Sette CVM, Bondarenko I, POD1UM-304 Study Team
doi: 10.1016/S2213-2600(25)00209-7
Lung Cancer
Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer a Systemic Review and Meta-analysis
Clin Lung Cancer
Choucair K, Jang H, Jalal SI, Hadid T, Uprety D, Kim S, Mamdani H
doi: 10.1016/j.cllc.2025.10.014
Lung Cancer
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer
Eur J Cancer
Matsumoto K, Yamamoto Y, Shiroyama T, Kuge T, Miyazaki A, Komuta K, Tamiya M, Nishino K, Tsukaguchi A, Tamiya A, Mihashi Y, Uchida J, Mori M, Yamauchi K, Suzuki H, Kinehara Y, Moritomo K, Shoshihara N, Machiyama H, Kanaoka K, Tobita S, Ueno K, Niki T, Tetsumoto S, Nishikawa Y, Morimura O, Kato S, Yoneda M, Azuma K, Osa A, Minami T, Nagatomo I, Takeda Y, Kumanogoh A
doi: 10.1016/j.ejca.2026.116902